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ABSTRACT
OBJECTIVE
To assess the magnitude and duration of any 
hypothesised protective effect of household exposure 
to a child with varicella on the relative incidence of 
herpes zoster in adults.
DESIGN
Self controlled case series.
SETTING
UK general practices contributing to Clinical Practice 
Research Datalink.
PARTICIPANTS
9604 adults (≥18 years) with a diagnosis of herpes 
zoster (in primary care or hospital records) between 
1997 and 2018, who during their observation period 
lived with a child (<18 years) with a diagnosis of varicella.
MAIN OUTCOME MEASURES
Relative incidence of herpes zoster in the 20 
years after exposure to a child with varicella in the 
household compared with baseline time (all other 
time, excluding the 60 days before exposure).
RESULTS
6584 of the 9604 adults with herpes zoster (68.6%) 
were women. Median age of exposure to a child 
with varicella was 38.3 years (interquartile range 
32.3-48.8 years) and median observation period 
was 14.7 (11.1-17.7) years. 4116 adults developed 
zoster in the baseline period, 433 in the 60 days 
before exposure and 5055 in the risk period. After 
adjustment for age, calendar time, and season, 
strong evidence suggested that in the two years 
after household exposure to a child with varicella, 
adults were 33% less likely to develop zoster 
(incidence ratio 0.67, 95% confidence interval 0.62 
to 0.73) compared with baseline time. In the 10-20 
years after exposure, adults were 27% less likely to 
develop herpes zoster (0.73, 0.62 to 0.87) compared 
with baseline time. A stronger boosting effect was 
observed among men than among women after 
exposure to varicella.
CONCLUSIONS
The relative incidence of zoster was lower in the 
periods after exposure to a household contact with 
varicella, with modest but long lasting protective 
effects observed. This study suggests that exogenous 
boosting provides some protection from the risk 
of herpes zoster, but not complete immunity, as 
assumed by previous cost effectiveness estimates of 
varicella immunisation.
Introduction
Primary infection with varicella zoster virus causes 
varicella (known commonly as chickenpox), typically 
in children. Herpes zoster (or shingles) arises from 
reactivation of latent varicella zoster virus following 
reduced cell mediated immunity, some years after the 
primary infection. Uncomplicated zoster is typically 
a mild, self limiting condition, but complications can 
occur,1 some of which, such as encephalitis, lead to 
severe illness, high healthcare costs, and mortality,2 
whereas others, such as post-herpetic neuralgia 
and Ramsay Hunt syndrome, can seriously affect 
quality of life.2-4 In 1965, Hope-Simpson proposed 
that immunity to the varicella zoster virus is boosted 
through exposure to varicella contacts,5 later called 
the exogenous boosting hypothesis, as well as 
asymptomatic reactivation of varicella zoster virus, 
called endogenous boosting. Although a varicella 
vaccine is available, in many countries, including 17 
European countries (including the United Kingdom), 
New Zealand, and China, it is not part of routine 
childhood vaccination programmes.6 This is partly 
because of concerns that its introduction would lead to 
a temporary increase in the number of cases of herpes 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Hope-Simpson’s exogenous boosting hypothesis (that exposure to children with 
varicella during adulthood boosts immunity to varicella zoster virus, thereby 
preventing zoster) has gained widespread credence from epidemiological 
studies, but more recent immunological data suggest that boosting may not be 
long lasting
Epidemiological data to support the findings from immunological studies are 
limited
The hypothesis is important for policymakers relying on cost effectiveness 
analyses to make recommendations about introducing universal childhood 
varicella vaccination so is particularly relevant to the UK
WHAT THIS STUDY ADDS
In this self controlled case series study of UK adults with both household 
exposure to varicella and an episode of zoster, strong evidence suggests that 
exposure to varicella is associated with a reduction in risk of zoster by around 
30% over 20 years 
These findings cannot be used to justify for or against specific vaccination 
schedules
They do, however, suggest that previous mathematical models, estimating the 
effect of exogenous boosting in childhood varicella vaccination policy in the 
UK, that assume complete immunity for between two and 20 years may need 
revisiting
 o
n
 11 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l6987 on 22 January 2020. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.l6987 | BMJ 2020;368:l6987 | the bmj
zoster for 30-50 years, following removal of circulating 
varicella zoster virus.7
Although not universally accepted, epidemiological 
risk factor studies assessing the risk of zoster after 
exposure to varicella, and immunological studies 
assessing varicella zoster virus specific immunity after 
exposure to varicella, provide some credence to the 
exogenous boosting hypothesis.8-10 What is less well 
understood is the degree and duration of any protection 
conferred from re-exposure to varicella on future risk 
of zoster. Some cost effectiveness analyses informing 
varicella vaccination policy assume that exogenous 
boosting provides complete protection from zoster for 
up to 20 years, after which individuals revert to full 
susceptibility (the temporary immunity hypothesis).11 
Others, however, incorporate different assumptions12—
for example, that exposure to varicella confers partial 
protection that wanes but can accumulate on repeated 
exposure (the progressive immunity hypothesis).13 
Lack of understanding about the role of exogenous 
boosting has meant public health decision making 
relies on mathematical models based on varied, and 
largely unsubstantiated, assumptions.13 14
Model based projections predict a higher incidence 
of zoster after varicella vaccination, resulting from a 
reduction in exogenous boosting, with zoster incidences 
peaking around 30 years after implementation in 
individual based models15 and 20 years in older 
deterministic models. Real-world evidence to date, 
however, does not entirely support these predictions. 
In the United States—the only country with a universal 
two dose varicella vaccination programme (introduced 
in 2007) of sufficient length for potential changes in 
zoster incidence to be observed—evidence suggests 
zoster began increasing before the introduction of the 
programme and continued to increase at similar rates 
after implementation.16 17 In Australia, where a state 
funded one dose varicella vaccination programme 
has been in place since 2006, no increases in hospital 
admissions for zoster have been observed.18 This might 
be explained by low varicella vaccine coverage or 
initial insufficient one dose vaccine schedules, or both, 
allowing ongoing transmission of the varicella zoster 
virus with some exogenous boosting. Changes in zoster 
incidence might also be explained by demographic 
changes, such as declining birth rates19 and the 
introduction of a vaccine against zoster. The lack of 
the predicted increase in zoster after routine varicella 
vaccination questions whether varicella zoster virus 
boosting from exposure to varicella contacts is as 
important as thought at a population level.8 17
Given the sparse empirical evidence about the 
exogenous boosting hypothesis, we carried out a self 
controlled case series to estimate the relative risk of 
zoster over time after exposure to a household contact 
with varicella.
Methods
Data source
Data were obtained from the UK Clinical Practice 
Research Datalink (CPRD)20 linked to the hospital 
episode statistics, Office for National Statistics death 
registrations, and index of multiple deprivation data. 
CPRD contains anonymised primary care records from 
around 9% of the UK population, registered at more 
than 700 general practices.21 Continuous CPRD data 
are available for each patient, including diagnoses 
(recorded using Read codes), prescriptions (recorded 
using British National Formulary codes), and basic 
demographic data. Individuals registered in CPRD 
are representative of the UK population for age and 
sex.20 About 80% of CPRD practices in England are 
eligible for linkage with hospital episode statistics, 
Office for National Statistics, and index of multiple 
deprivation data; data are linked by the trusted third 
party NHS Digital using deterministic methods.22 
To maximise study power, in our primary analysis 
we included patients with and without linked data. 
Hospital episode statistics data contains all NHS 
funded hospital admissions in England since 1997, 
including diagnoses (coded using international 
classification of diseases, 10th revision).20 Index of 
multiple deprivation data provide patient level data 
by mapping patients’ postcode to geographical areas 
with predefined deprivation scores; index of multiple 
deprivation combines several indicators, chosen to 
cover a range of economic, social, and housing issues, 
into a single deprivation score.20
Study design
We carried out a self controlled case series analysis 
(an overview of the method is provided elsewhere23), 
which is a relatively novel epidemiological study 
design where individuals act as their own controls. 
Comparisons are made within individuals rather 
than between individuals as in a cohort or case-
control study. Thus, only those who have experienced 
both the outcome and the exposure of interest are 
included.24 25 Self controlled case series investigate 
the effect of a time varying exposure on an outcome 
by comparing the incidence of adverse events within 
periods of hypothesised excess risk from exposure 
with incidence during all other times. The temporal 
association between an exposure and an event is 
estimated using Poisson models to derive incidence 
rate ratios, comparing the rate of the outcome during 
an individual’s periods of exposure and non-exposure. 
Self controlled case series have been applied in 
various settings and are particularly useful when 
an appropriate comparison group of unexposed 
individuals is difficult to identify.23
Selection of participants and observation period
The source population comprised all adults with at 
least one day of registration with a CPRD practice 
meeting CPRD quality control standards between 1 
April 1997 (ie, date from which linked hospital episode 
statistics data were available) to 31 July 2018. From the 
source population we identified those with a first ever 
diagnosis of zoster who additionally had a child (<18 
years) in the household (same family practice number) 
with a varicella record. A new family practice number 
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variable is generated by the general practice software 
when patients register with a general practitioner 
or move address, assigning the same number to all 
those with the same address (CPRD Knowledge Centre, 
personal communication, 2017).
We began the observation period at the latest of; 
12 months after the beginning of CPRD follow-up26 
(to ensure zoster diagnoses represented new cases, 
with CPRD follow-up defined as the latest of patient 
registration date at the practice and date at which the 
practice data met CPRD quality control standards20), 
the date patients became 18 years of age, or the 1 April 
1997 (study start date). The end of the observation 
period was defined as the earliest of date of death, date 
on which patients left the practice, day of the last data 
collection from the practice, or 31 July 2018 (study end 
date).
Figure 1 illustrates the self controlled case series 
framework for an individual participant, including 
their pre-exposure period, risk periods, and unexposed 
observation periods.
Pre-exposure period—Patients with zoster are 
infectious during the blister phase, typically lasting 
7-10 days from rash onset (with complete healing 
within 28 days),27 during which time they might 
infect a susceptible contact. The incubation period 
for varicella is 10-21 days.28 As such, any susceptible 
contact might develop varicella within 10 to 49 days 
of the zoster diagnosis. We therefore excluded a period 
of 60 days before exposure to varicella from baseline 
(unexposed) time, to allow for a zoster event resulting 
in an increased risk of varicella. The 60 day period was 
chosen to represent a conservative pre-exposure period 
(and variations were explored in post hoc sensitivity 
analyses).
Risk (exposed) periods—A priori we planned to 
have a fixed 20 year risk period, consistent with the 
duration of boosting assumed in the most conservative 
of cost effectiveness analyses of vaccines against 
varicella zoster virus.11 We subdivided exposure time 
into five risk windows (0-<2, 2-<5, 5-<10, 10-20 years) 
and used standard self controlled case series analytical 
techniques, where the incidence of zoster is assumed 
to be constant during a risk window, as risk of zoster 
might vary within this 20 year risk period.
Baseline (unexposed) periods—All other observation 
time made up the baseline (unexposed) period—that 
is, all time before 60 days before exposure to varicella 
in the household, and all time following the 20 years 
after exposure to varicella.
Self controlled case series assumptions
The self controlled case series method relies on 
three key assumptions. Firstly, recurrent events (or 
outcomes) must be independent—that is, the chance of 
a second event is not influenced by having a first event. 
Zoster can recur (although recurrence is rare in people 
who are immunocompetent),5 29-32 and therefore this 
assumption could be violated; however, when the event 
is rare (which applies to zoster), considering only the 
first zoster episode is a valid approach to overcoming 
this potential bias.24 33 Secondly, the occurrence of 
an event (zoster) should not alter the probability 
of subsequent exposure (to varicella). People with 
zoster are infectious during the blister phase and this 
might result in varicella if they are in direct contact 
with susceptible contacts. As zoster could lead to an 
increased incidence of varicella this might artificially 
inflate the relative rate of zoster events occurring in 
unexposed versus exposed (to varicella) periods. This 
can be overcome by removing a predefined period 
before (varicella) exposure from all other unexposed 
(baseline) time.34 Thirdly, the event of interest must 
not censor the observation period—for example, if the 
zoster event increases the likelihood of death. This 
assumption is fulfilled, as zoster is rarely associated 
with increased mortality.35 Supplementary box e-1 
provides a detailed discussion of these fundamental 
assumptions.
Exposures
Household contact with varicella—To identify child (<18 
years) household contacts with varicella we searched 
for all varicella cases recorded in primary care (CPRD) 
and as part of a hospital admission (hospital episode 
statistics, any diagnostic field). We then used the family 
practice number to match these cases of varicella with 
cases of zoster. Exposure to varicella had to occur 
during the observation period of adults with zoster. 
If varicella was recorded in both hospital episode 
statistics and CPRD within the same contact, we used 
the earliest recorded diagnosis. For varicella cases 
identified in hospital episode statistics, we defined 
the date of varicella diagnosis as the date patients 
were admitted. To ensure we captured incident cases 
of varicella, we excluded those contacts without six 
Start of
observation
Exposure to
varicella case
End of
observation
Unexposed baseline period 60 days pre-exposure to varicella case period
Exposed risk period (years), divided into four risk
windows following exposure to varicella case:
0-<2 2-<5 5-<10 10-20
Fig 1 | Graphical representation of framework for self controlled case series for an individual with more than 20 years 
of observation
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months of CPRD follow-up, before their first varicella 
record.
Household contacts with acute gastroenteritis—
We repeated the self controlled case series using 
household contacts with a child (<18 years) with 
acute gastroenteritis as a negative control exposure. 
Before the introduction of a routine vaccination 
programme in 2013, rotavirus was the most common 
cause of acute gastroenteritis. Rotavirus would not 
plausibly be expected to influence the future risk of 
zoster. Therefore, we did not expect to see a temporal 
association between exposure to gastroenteritis and 
zoster incidence; any association would call into 
question exogenous boosting as the interpretation 
of a positive result in the main analysis. We selected 
only gastroenteritis events up to 2012 (as rotavirus 
vaccination was introduced in 2013) and only the 
first episode of gastroenteritis. Acute gastroenteritis 
was defined using a comprehensive list of Read 
and hospital episode statistics codes, to identify 
primary care related (general practitioner diagnosed) 
and secondary care related (hospital diagnosed) 
events, respectively, until December 2012. Hospital 
episode statistics ICD-10 codes included A00-A09, 
for infectious intestinal diseases listed in any field. 
Read codes included infectious gastroenteritis and 
gastroenteritis of unspecified type (eg, combined 
diarrhoea and vomiting).36
Outcome
The primary outcome was a first ever episode of acute 
zoster. We included zoster diagnosed in adults (≥18 
years) during the observation period and excluded 
those with a history of post-herpetic neuralgia. We 
identified zoster in CPRD or hospital episode statistics 
(recorded in any diagnostic position of any episode 
of a hospital admission), using the earliest recorded 
diagnosis if zoster was recorded more than once. For 
zoster cases identified as part of a hospital admission, 
we defined the date of zoster diagnosis as the date the 
episode started (period of hospital admission under 
the care of a specific doctor).
Covariates
A major strength of the self controlled case series 
design is that individuals serve as their own controls. 
The methodology therefore implicitly accounts 
for factors that remain constant over time (eg, 
sex). Consequently we captured only time varying 
covariates, age, calendar time, and season. We chose 
40 age bands using quantiles (equal sized groups) of 
age at first zoster diagnosis.37 Calendar period was 
captured (using two year time periods) to adjust for 
changes in clinical, diagnostic, and administrative 
practices over the study period that could influence 
how exposures and outcomes were recorded. As 
varicella is more common in winter and spring, we 
captured season to account for any confounding 
effects, defined as winter (December-February), spring 
(March-May), summer (June-August), and autumn 
(September-November).
Age (<50 and ≥50 years, to crudely separate 
exposure of parent from that of grandparent), sex (men 
and women), and severe immunosuppression status 
at household exposure to varicella were assessed 
as effect modifiers. Severe immunosuppression 
was defined as conditions or drugs that are listed 
as contraindications for the live zoster vaccine in 
the UK, which was introduced in 2013 to limited 
age groups38; if vaccinated, those with primary or 
acquired immunodeficiency are considered to be at 
risk of developing a varicella-like or zoster illness 
from the live vaccine virus strain. Immunosuppressive 
diagnoses and drugs were identified in primary 
care (CPRD) and secondary care (hospital episode 
statistics, any diagnostic position) records and were 
time updated (that is, patient’s immunosuppression 
status could vary over his or her observation period: 
see supplementary box e-2 for more details). We also 
used information on quintiles of the patient level index 
of multiple deprivation to describe the cohort.
The morbidity codes used in this study are 
available for download: https://doi.org/10.17037/
DATA.00001158.
Statistical analyses
Data management and analyses were carried out in 
STATA/SE 15.1 and RStudio (self controlled case series 
package).37 We used conditional Poisson regression to 
calculate incidence rate ratios comparing the incidence 
of zoster after exposure to varicella with baseline 
(unexposed) time.24 We first adjusted for age (defined 
by 40 quantiles of age at zoster diagnosis), then added 
calendar time and season. If participants had multiple 
exposures to household contacts with varicella during 
their observation period, we considered only the first 
exposure in the primary analysis (multiple exposures 
were explored in a secondary analysis). We similarly 
ignored secondary episodes of zoster.
Secondary analyses included investigating 
whether the association between exposure to 
varicella and risk of zoster varied by age, sex, and 
severe immunosuppression status of the zoster case; 
investigating whether there was a dose-response 
effect with repeated varicella exposures (accounting 
for repeat exposures by ending the last day of a risk 
period the day before a subsequent exposure to 
varicella, see supplementary figure e-4 for graphical 
representation); and repeating the main self controlled 
case series analysis using gastroenteritis exposure as 
a negative control exposure. Finally, as the analyses 
suggested boosting might last beyond 20 years we 
chose not to explore shorter risk periods (as per 
protocol) but instead explored an indefinite risk period 
after exposure to varicella contacts.
Sensitivity analyses
We checked our assumptions through several 
sensitivity analyses: 1) using a spline based age 
effect, where the relative age effect is represented 
by a smooth function obtained by splicing together 
polynomials of low dimension, to ensure we had fully 
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adjusted for age effects; 2) restricting to patients with 
linked hospital episode statistics records only (as 
linked patients had better capture of our exposure 
and outcome); 3) restricting to households with a 
single child aged <16 years (to reduce the likelihood 
of misclassifying exposure time); 4) excluding those 
with recurrent zoster during the observation period 
(with the recurrent episode defined as a zoster record 
five years after first zoster record); 5) excluding those 
with a zoster vaccination; and 6) assessing hip fracture 
as an alternative outcome, which is strongly associated 
with increasing age (if the age adjustment in our 
primary analysis was sufficient, we should observe 
a null association between exposure to varicella and 
hip fracture). In post hoc analyses we varied the pre-
exposure window, defining it as 30 and 90 days, to 
explore whether these different durations affected the 
study findings.
Patient and public involvement
Neither patients nor the public were involved in 
developing the research question and study or in the 
design, management, or interpretation of this study.
Results
Overall, 9604 adults with zoster were exposed to a 
child contact with varicella in the household during 
the study period (supplementary fig e-1), of whom 
39 (0.4%) received a diagnosis of zoster in hospital. 
The median age at first zoster diagnosis was 41.1 
years (interquartile range 33.1-51.3 years) and at 
first known exposure to varicella was 38.3 (32.3-
48.8) years (table 1). The median age of the children 
at varicella episode was 3.8 (2.3-5.7) years. The 
median observation period was 14.7 (11.1-17.7) 
years. In total, 118 (1.2%) participants were severely 
immunosuppressed at the time of exposure to 
varicella. Participants’ ages varied widely at the start 
of the observation period (supplementary fig e-2) 
and at exposure to varicella and diagnosis of zoster 
(supplementary fig e-3).
In the unadjusted analysis, the relative risk of zoster 
was observed to increase 10-20 years after exposure, 
which would be expected, because as the risk period 
progresses people age and become more susceptible to 
zoster (table 2). After adjustment for the confounding 
effects of age, exposure to a household contact with 
varicella was associated with a reduced risk of zoster 
among adults for up to 20 years (table 2); adults were 
33% less likely to develop zoster within two years 
of exposure to varicella (incidence ratio 0.67, 95% 
confidence interval 0.62 to 0.73) than during baseline 
(unexposed) time. The incidence ratio moved closer to 
1 with time since varicella exposure; after exclusion of 
the baseline and pre-exposure groups, some evidence 
suggested a linear trend (P=0.03, comparison between 
a model with no exposure group and one with linear 
exposure). Ten to 20 years after exposure to a varicella 
contact, adults were 27% less likely to develop zoster 
(incidence ratio 0.73, 95% confidence interval 0.62 to 
0.87) than during baseline (unexposed) time.
The effect of exposure to varicella on risk of 
zoster varied between men and women (P<0.001 for 
interaction); varicella exposure was more protective 
among men than among women (table 3). We found no 
evidence of effect modification by immunosuppression 
status (P=0.53) or age at exposure to varicella (P=0.65).
In total, 7972 (83.0%) participants had one 
recorded exposure to a household contact with 
varicella during the observation period, 1449 (15.1%) 
had two exposures, and the remaining 183 (1.9%) had 
three or more exposures. The median time between 
first and second exposure was 127 days (interquartile 
range 14-1541 days). Repeated household exposure to 
varicella was associated with a reduced risk of zoster, 
but no more than the reduced risk observed for the first 
exposure (table 4).
Exposure to a household contact with gastroenteritis 
was not associated with zoster (supplementary 
tables e-1 and e-2); within two years of exposure to 
gastroenteritis, no evidence was found of a decreased 
risk of zoster (incidence ratio 0.95, 95% confidence 
interval 0.87 to 1.04). When the risk period was 
defined as indefinite after exposure to varicella (that 
is, all observation time after exposure to varicella, 
not limited to 20 years after exposure to varicella), 
no evidence of an association was found between 
exposure to varicella and risk of zoster 20 years after 
exposure (incidence ratio 1.21, 95% confidence 
interval 0.54 to 2.74; see supplementary table e-3); 
however, the confidence intervals were wide, as only 
seven zoster events occurred.
Sensitivity analyses
When modelling age as a spline based function, 
the effect of exposure to varicella on risk of zoster 
was consistent with the main analysis, suggesting 
adequate adjustment for age (supplementary table 
e-4). Excluding those without linked hospital episode 
statistics data (n=4123), those with recurrent 
zoster (n=132), and those receiving the live zoster 
vaccine (n=212) made little difference to the results 
(supplementary table e-4). In single child households, 
the point estimates were all closer to 1 (supplementary 
table e-4). Although exposure to varicella appeared to 
be associated with increased risk of hip fracture, after 
adjustment for age in 40 quantiles, the association was 
much attenuated (supplementary tables e-5 and e-6). 
Finally, shortening the pre-exposure window to 30 
days strengthened the relative risk of zoster, whereas 
lengthening the window to 90 days attenuated the 
relative risk. When the pre-exposure time window was 
varied, however, the relative risks for the individual 
risk windows were broadly similar to those of the main 
analyses (supplementary table e-7).
Discussion
This self controlled case series study found a reduced 
risk of zoster associated with exposure to a household 
contact with varicella, with modest but long lasting 
protective effects observed. Strong evidence suggests 
that in adults the risk of zoster within two years of 
 o
n
 11 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l6987 on 22 January 2020. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.l6987 | BMJ 2020;368:l6987 | the bmj
exposure to a child with varicella in the household 
was 33% lower than in the baseline period, and in the 
10-20 years post-exposure the risk was 27% lower. No 
evidence was found to indicate that protection against 
reactivation of the varicella zoster virus accumulates 
on repeated exposure (the progressive immunity 
hypothesis); however, the study might have been 
underpowered to detect an effect. These data challenge 
the assumption previously used in public health policy 
modelling in certain countries, including the UK, 
that through exogenous boosting people exposed to 
varicella are completely immune to zoster for between 
two and 20 years.39
Strengths and limitations of this study
In this study we used a self controlled case series 
design to test the duration of varicella zoster virus 
exogenous boosting, which enabled us to control for 
confounding between participants and capture the 
precise timing of the included varicella and zoster 
diagnoses. Although our research question potentially 
violates some of the assumptions of self controlled 
case series methodology, we used recommended 
approaches to tackle these issues, including studying 
only first events and including a pre-exposure period 
in the analyses (supplementary box e-1). We controlled 
for the confounding effects of age, as evidenced by 
our negative outcome analysis (exploring the link 
between varicella contact and hip fracture); after 
exposure to varicella the relative rate of hip fractures 
was observed to increase substantially over time, but 
after adjustment for age as a spline based effect, the 
associations were no longer evident.
Capture of zoster cases is likely to be reliable and 
comprehensive. Zoster is typically a straightforward 
diagnosis, as it has a characteristic dermatomal 
distribution. Evidence suggests that most people 
with zoster seek out healthcare: a US based health 
and retirement survey among adults aged 55 and 
older reported that more than 91% who self reported 
herpes zoster had sought medical care40; another US 
based survey about immunisation practices in the US 
among adults aged 60 and older found that 95% of 
those who knew they had zoster sought care41; and 
a community based retrospective survey in Beijing, 
China (all ages) found that 92.4% of participants had 
sought healthcare for zoster.42 Varicella is similarly 
a straightforward diagnosis, so our records are likely 
to be reliable. We used a population based sample, 
representative of the UK population for age, sex, and 
ethnicity20 and therefore our findings are likely to be 
generalisable to the UK population.
This study also has some limitations. Varicella is 
likely to be under-ascertained in UK electronic health 
records; varicella tends to be a mild, self limiting 
condition that does not require a visit to the doctor, 
and consultations with doctors for varicella have 
been declining in the UK (between 2004 and 2014 by 
around 20% in 1-3 year olds and 6% in 4-6 year olds).43 
This misclassification of varicella exposure might 
result in some true exposed time being misclassified 
as unexposed time (if the household contacts with 
varicella did not attend their general practice or our 
observation period did not cover the time of first 
Table 1 | Characteristics of 9604 adults with zoster exposed to a child with varicella in 
the household. Values are numbers (percentages) unless stated otherwise
Characteristics Estimates
Median (interquartile range) age at first zoster diagnosis (years) 41.1 (33.1-51.3)
Median (interquartile range) age of household varicella contact at diagnosis (years) 3.8 (2.3-5.7)
Median (interquartile range) age of exposure to household varicella contact (years) 38.3 (32.3-48.8)
Median (interquartile range) years of observation 14.7 (11.1-17.7)
Women 6584 (68.6)
Eligible for hospital episode statistics linkage 5481 (57.1)
Fifth of patient level index of multiple deprivation:
 1st (least deprived) 1345 (14.0)
 2nd 1198 (12.5)
 3rd 1124 (11.7)
 4th 993 (10.3)
 5th (most deprived) 876 (9.1)
Missing 4068 (42.4)
Start of observation period in adults:
 1997-99 3875 (40.3)
 2000-04 3936 (41.0)
 2005-09 1355 (14.1)
 2010-15 407 (4.2)
 2015-18 31 (0.3)
Season of exposure to household varicella contact:
 Winter (December-February) 2341 (24.4)
 Spring (March-May) 3438 (35.8)
 Summer (June-August) 2488 (25.9)
 Autumn (September-November) 1337 (13.9)
Severely immunosuppressed at household exposure to varicella contact 118 (1.2)
Table 2 | Adjusted incidence ratios for zoster in 9604 adults during risk periods after household exposure to a child with 
varicella
Time period
No of zoster 
events
Person years of 
 observation
Crude incidence ratio 
(95% CI)
Age adjusted incidence 
ratio* (95% CI)
Age, calendar time, and 
 season adjusted incidence 
ratio* (95% CI)
Baseline† 4116 56 417 1.00 1.00 1.00
60 days pre-exposure 433 1539 3.17 (2.86 to 3.51) 2.89 (2.60 to 3.21) 2.87 (2.58 to 3.19)
Post-exposure risk period (years):
 0-<2 1177 18 031 0.77 (0.72 to 0.82) 0.68 (0.63 to 0.74) 0.67 (0.62 to 0.73)
 2-<5 1432 22 2901 0.85 (0.80 to 0.91) 0.70 (0.64 to 0.77) 0.69 (0.63 to 0.76)
 5-<10 1546 24 620 0.96 (0.89 to 1.02) 0.70 (0.63 to 0.79) 0.69 (0.61 to 0.77)
 10-20 900 13 317 1.25 (1.14 to 1.37) 0.77 (0.65 to 0.90) 0.73 (0.62 to 0.87)
*Age defined by 40 quantiles of age at event (herpes zoster); calendar time defined as 1997-98, 1999-2000, 2001-02, 2003-04, 2005-06, 2007-08, 
2009-10, 2011-12, 2013-14, 2015-16, 2017-18; and season defined as winter (December-February), spring (March-May), summer (June-August), and 
autumn (September-November).
†All time from observation start to 60 days pre-exposure, and after the 20 years after exposure: seven zoster events occurred after the 20 years after 
exposure.
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exposure) and could therefore bias the effect estimate 
towards the null, thus potentially underestimating 
the effect of exogenous boosting. We were not able 
to capture occupational exposure to varicella, such 
as in healthcare or childcare workers: about two 
million people, or 5% of the population of England, 
during their work could be exposed to children 
with varicella.44 45 Household cases of varicella are, 
however, likely to cluster together; studies suggest 
that about 78% of healthy household contacts develop 
varicella.46 In this case, if only a second or subsequent 
child presented to the doctor, the true first exposure 
would likely be in the 60 day pre-exposure period 
(because household clusters tend to occur within a few 
weeks of each other). This would mean that our current 
estimate for 0-<2 years is biased away from the null—
that is, we have overestimated boosting effects in the 
0-<2 years’ risk period.
Owing to the under-ascertainment of varicella in 
medical records, it is possible that those represented 
in general practice records might have more severe 
varicella. If this was the case, we would expect the 
cases to have a relatively higher viral load than the 
average individual with varicella, and potentially this 
would result in a greater degree of boosting in exposed 
adults. Therefore, by capturing more severe varicella 
cases, our study might have overestimated the degree 
of exogenous boosting.
We did not validate the family number variable 
(which identifies all those living in the same 
household), so we might have wrongly identified those 
as living in the same household. People can move in or 
out of households and people living together could be 
registered at different practices. This misclassification 
of varicella exposure is likely to be non-differential for 
zoster and thus would bias the effect estimates towards 
the null. However, we ensured that exposure to 
varicella occurred during the observation period of the 
participant with zoster to reduce the misclassification 
of varicella. We also removed diagnoses of varicella 
recorded in the six months following a person’s 
registration at their general practice, to ensure 
varicella diagnoses were incident and that we were 
not capturing historical varicella recorded as part of 
practice registration.
CPRD registered patients leaving one CPRD practice 
and entering another are not currently identifiable 
in the database. In theory therefore it is possible 
for patients to be entered twice in CPRD and thus 
appearing as two different people. However, patients’ 
medical records are transferred to their new practice. 
Therefore, any such patient would have a record, and 
therefore a history, of zoster before CPRD follow-up 
and be excluded from our study population during the 
time they were in their second practice. Furthermore, 
the rate of recurrent zoster is low (estimated to be 
between 1% and 6%)5 29-32; therefore if patients have 
a diagnosis of zoster recorded within one medical 
practice and transfer to another in CPRD, they are 
unlikely to have been included in our study again as 
their risk of varicella zoster virus being reactivated 
again is low.
We found no evidence of effect modification by 
immunosuppression status. It could be hypothesised 
that patients with severe immunosuppression might 
not experience the same degree of exogenous boosting, 
compared with immunocompetent patients, when 
exposed to a child with varicella; if their immune 
Table 3 | Incidence ratios for zoster in 9604 adults during risk periods after household 
exposure to a child with varicella, by other factors
Time period
No. of zoster 
events
Age, calendar time, and season 
adjusted incidence ratio* (95% CI)
P value for 
interaction†
Sex
Men:
 Baseline‡ 1354 1.00
P<0.001
 60 days pre-exposure 188 3.58 (3.05 to 4.20)
 Years post-exposure:
  0-<2 336 0.55 (0.48 to 0.62)
  2-<5 417 0.57 (0.50 to 0.65)
  5-<10 464 0.57 (0.49 to 0.67)
  10-20 261 0.59 (0.48 to 0.74)
Women:
 Baseline‡ 2762 1.00
 60 days pre-exposure 245 2.49 (2.17 to 2.85)
 Years post-exposure:
  0-<2 841 0.74 (0.68 to 0.81)
  2-<5 1015 0.76 (0.69 to 0.84)
  5-<10 1082 0.76 (0.67 to 0.86)
  10-20 639 0.82 (0.68 to 0.98)
Age at household exposure to varicella (years)
18-49:
 Baseline‡ 2834 1.00
P=0.65
 60 days pre-exposure 350 2.90 (2.58 to 3.26)
 Years post-exposure:
  0-<2 924 0.66 (0.61 to 0.72)
  2-<5 1133 0.68 (0.62 to 0.75)
  5-<10 1288 0.69 (0.60 to 0.78)
  10-20 808 0.75 (0.63 to 0.90)
≥50:
 Baseline‡ 1282 1.00
 60 days pre-exposure 83 2.72 (2.16 to 3.42)
 Years post-exposure:
  0-<2 253 0.72 (0.61 to 0.83)
  2-<5 299 0.74 (0.63 to 0.87)
  5-<10 258 0.70 (0.56 to 0.86)
  10-20 92 0.67 (0.48 to 0.93)
Immunosuppression status at exposure to varicella 
Immunocompetent:
 Baseline‡ 4056 1.00
P=0.53
 60 days pre-exposure 424 2.84 (2.55 to 3.16)
 Years post-exposure:
  0-<2 1162 0.67 (0.62 to 0.73)
  2-<5 1413 0.69 (0.63 to 0.75)
  5-<10 1537 0.69 (0.61 to 0.77)
  10-20 894 0.74 (0.62 to 0.87)
Immune suppressed:
 Baseline‡ 60 1.00
 60 days pre-exposure 9 4.74 (2.30 to 9.79)
 Years post-exposure:
  0-<2 15 0.74 (0.41 to 1.35)
  2-<5 19 0.95 (0.53 to 1.71)
  5-<10 9 0.52 (0.23 to 1.18)
  10-20 6 0.94 (0.33 to 2.68)
*Age defined by 40 quantiles of age at event (herpes zoster); calendar time defined as 1997-98, 1999-2000, 
2001-02, 2003-04, 2005-06, 2007-08, 2009-10, 2011-12, 2013-14, 2015-16, 2017-18; and season 
defined as winter (December-February), spring (March-May), summer (June-August), and autumn (September-
November).
†Calculated using likelihood ratio test.
‡All time from observation start to 60 days pre-exposure, and after the 20 years after exposure.
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system is weakened, they may be unable to mount an 
effective immune response. Unfortunately, our study 
was underpowered to detect a difference in the boosting 
effect among immunosuppressed people, as only 
1.2% of our study sample were immunosuppressed at 
exposure to varicella.
The study design required patients with zoster to be 
living with a child with varicella, therefore the study 
cohort is younger than a general population with 
zoster. If younger adults are more likely to attend their 
general practice only when zoster is severe, this could 
affect the generalisability of our study by making it 
more applicable to how exposure to varicella in the 
household protects against severe cases of zoster. 
However, when we restricted our analysis to adults 
aged 50 and older at exposure to varicella, a similar 
pattern of association was observed, with no evidence 
of effect modification by age (table 3). This suggests 
that although the median age of our study cohort (at 
exposure to varicella) was low, the findings can be 
generalised to older people.
Finally, bias could be introduced if inclusion in our 
study (that is, visits to a general practitioner for zoster) 
is differential according to the timing of exposure to a 
household contact with varicella. All our comparisons 
were within person, therefore health seeking biases 
are less likely. However, an individual’s health seeking 
behaviour might vary over time. It is plausible that 
parents caring for children with varicella might be 
less likely to attend a general practice during the acute 
phase of zoster owing to child care responsibilities. 
This would result in slightly lower ascertainment of 
zoster in the week after a diagnosis of varicella, which 
could have pulled the association between exposure to 
varicella and risk of zoster towards the null for the first 
risk period (0-<2 years post-exposure).
Comparison with other studies
In a systematic review of epidemiological studies 
investigating the reduction in risk of zoster from 
exposure to varicella, 27 of 40 studies showed 
evidence of varicella zoster virus exogenous boosting, 
although the duration and magnitude of boosting 
could not be determined.8 The review identified nine 
epidemiological risk factor studies that investigated 
the risk of zoster after exposure to children generally 
and to children with varicella, four of which found 
evidence of varicella zoster virus exogenous boosting 
.8 Studies found that the degree of protection from 
exposure to children ranged from a 25%11 to 70%47 
reduced risk, with studies using different time frames 
and numbers of exposures to varicella. In our study we 
used medical record data on the timing of exposure 
to both zoster and varicella, and thus might offer 
more reliable estimates of effect than studies relying 
on patient recall47 or using living with children as a 
proxy for exposure to varicella contacts.11 The review 
also included four prospective immunological studies 
analysing immunity to varicella zoster virus after 
exposure to varicella, measured using antibody titres; 
however, only two studies had data for up to one 
year after exposure. One longitudinal study showed 
that among grandparents re-exposed to varicella, the 
associated increased immune response to varicella 
zoster virus (measured as varicella zoster virus specific 
T cell immunity and antibody titres) was not universal 
and was noticeable for less than one year.9 Our results, 
indicating that exposure to a varicella contact might 
protect against zoster for over two years, may reflect 
the difficulty in measuring the immune response to 
varicella zoster virus.
To date no clear-cut increase in zoster incidence 
attributed to routinely vaccinating against varicella 
has been observed, as predicted by modelling studies 
incorporating the exogenous boosting hypothesis.17 
The US has had a two dose varicella vaccination 
programme since 2007 and therefore could serve as 
a comparison to modelling predictions; here zoster 
incidence began increasing before the introduction 
of the vaccine.16 However, estimates of the timing of 
the first measurable increase in zoster vary according 
to the type of model and its assumptions, thus 
although the US has only seen a similar increase in 
zoster incidence as before varicella vaccination, it is 
possible that the “real” effect might only occur after 
more than 20 years from the vaccination programme 
being introduced. If, however, boosting does not 
provide complete immunity, as suggested by this self 
controlled case series, then the population impact of 
varicella vaccination on zoster incidence might not be 
as great as some model based studies predicted.15 A 
recent systematic review and meta-analysis of varicella 
vaccination and risk of zoster concluded that although 
Table 4 | Adjusted incidence ratios for zoster in 9604 adults during risk periods for those 
with one, two, or three or more recorded household varicella exposures
Varicella exposure and time period No. of zoster events
Age, calendar time, and season 
 adjusted incidence ratio* (95% CI)
Baseline† 4114 1.00
1st exposure
60 days pre-exposure 429 2.90 (2.61 to 3.23)
Years post-exposure:
 0-<2 1149 0.67 (0.62 to 0.72)
 2-<5 1372 0.70 (0.64 to 0.76)
 5-<10 1431 0.69 (0.62 to 0.77)
 10-20 811 0.75 (0.64 to 0.87)
2nd exposure
60 days pre-exposure 24 1.64 (1.09 to 2.48)
Years post-exposure:
 0-<2 53 0.60 (0.44 to 0.81)
 2-<5 63 0.73 (0.55 to 0.98)
 5-<10 50 0.68 (0.48 to 0.96)
 10-20 87 0.80 (0.59 to 1.07)
≥3rd exposure
60 days pre-exposure <5‡ 0.59 (0.08 to 4.23)
Years post-exposure:
 0-<2 <5‡ 0.34 (0.10 to 1.10)
 2-<5 <5‡ 0.39 (0.12 to 1.29)
 5-<10 7 1.16 (0.47 to 2.86)
 10-20 7 1.42 (0.52 to 3.85)
*Age defined by 40 quantiles of age at event (herpes zoster); calendar time defined as 1997-98, 1999-2000, 
2001-02, 2003-04, 2005-06, 2007-08, 2009-10, 2011-12, 2013-14, 2015-16, 2017-18; and season 
defined as winter (December-February), spring (March-May), summer (June-August), and autumn (September-
November).
†All time from observation start to 60 days pre-exposure, and after the 20 years after exposure.
‡Cell counts less than five have been suppressed to preserve anonymity.
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exogenous boosting is plausible at an individual level, 
no conclusive evidence exists to date that varicella 
vaccination has a substantial population level impact 
on zoster.17
A priori, we hypothesised that as women are more 
likely to be the primary caregiver and thus have more 
direct physical contact with children with varicella, 
the degree of protection gained from boosting would 
be greater among women. We found the opposite. This 
could suggest that men mount a more effective immune 
response when boosted by exposure to a varicella 
case; most childhood infections are more severe in 
boys than in girls,48 therefore this could lead to greater 
immune memory and greater potential for boosting. It 
is also well established that zoster occurs more often in 
women,49 supporting the hypothesis of lower residual 
immunity in women. Alternatively, women may have 
more exposures to children outside the household, so 
the household boosting effect in men is therefore more 
pronounced.
Conclusions and policy implications
These findings are important and timely given that 
certain countries (such as the UK12) are currently 
reviewing their varicella and zoster vaccination policy; 
this study suggests that in adults varicella zoster 
virus exogenous boosting does not provide complete 
immunity and therefore cost effectiveness analyses 
modelling the effect of varicella vaccination on zoster 
need to be revisited.
Future studies should substantiate these findings 
using different data sources; particular design 
improvements could be larger samples, to capture more 
individuals with repeated exposures to varicella (and 
thus better understand whether exogenous boosting 
with varicella zoster virus provides a fixed level of 
immunity or progressive immunity against zoster) 
and existing immunosuppression, older age samples 
with more adults aged 50 years and older where the 
burden of zoster exists, as well as data with better 
capture of exposure to varicella outside the household, 
particularly among grandparents.
This self controlled case series investigating the 
protective effect of exposure to a varicella case suggests 
exposure is associated with a 33% reduction in zoster 
incidence in the first two years, with some indication 
this effect wanes slightly but is maintained over the 
20 years from exposure to varicella. These findings 
are themselves unable to justify for or against specific 
vaccination schedules, but they do suggest that 
revised mathematical models are required to estimate 
the impact of varicella vaccination, with the updated 
assumption that exogenous boosting is incomplete 
and only reduces the risk of zoster by about 30%.
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